What medication sold under the name Adrucil uses the phenomenon of Thymineless death?
Thymineless death Thymineless death is the phenomenon by which bacteria, yeasts and mammalian cells undergo cell death when they are starved of thymidine triphosphate (dTTP), an essential precursor for DNA replication. This phenomenon underlies the mechanism of action of several antibacterial, antimalarial and anticancer agents, such as Trimethoprim, Sulfamethoxazole, Methotrexate and Fluorouracil.
Solriamfetol Solriamfetol (developmental code names JZP-110, ADX-N05, others) is a norepinephrine–dopamine reuptake inhibitor (NDRI) which is under development by Jazz Pharmaceuticals for the treatment of narcolepsy, sleep apnea, hypersomnia, and renal failure. It is a low-potency NDRI, with respective IC values for the dopamine and norepinephrine transporters of 2.9 and 4.4 μM, and shows a low abuse liability. As of July 2017, it is in phase III clinical trials for narcolepsy and sleep apnea, phase II clinical trials for hypersomnia, and phase I clinical trials for renal failure.